Shots:

• Janssen has initiated P-Ib proof-of-concept clinical trial assessing Guselkumab vs PBO in 72 patients with familial adenomatous polyposis (FAP). With the initiation of P-Ib study for FAP- MorphoSys will receive milestones from Janssen
• Earlier- Janssen collaborated with MorphoSys to develop Guselkumab utilizing MorphoSys's HuCAL antibody technology (Human Combinatorial Antibody Library)- a platform for invitro generation of Abs
• Tremfya(R) (guselkumab) is an anti-IL-23 mAb and has received approval in the US- Canada- EU for plaque psoriasis and in Japan for psoriasis- psoriatic arthritis & palmoplantar pustulosis

Ref: MorphoSys | Image: Janssen